Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M.

J Clin Oncol. 2009 Sep 10;27(26):4274-80. doi: 10.1200/JCO.2009.22.0541. Epub 2009 Aug 3.

PMID:
19652055
2.

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, Germonpré P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M.

J Clin Oncol. 2009 May 20;27(15):2523-9. doi: 10.1200/JCO.2008.18.6015. Epub 2009 Mar 30.

PMID:
19332730
3.

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE.

J Clin Oncol. 2008 Nov 20;26(33):5407-15. doi: 10.1200/JCO.2008.17.3138. Epub 2008 Oct 20.

PMID:
18936474
4.

Targeting angiogenesis in the treatment of lung cancer.

Wheatley-Price P, Shepherd FA.

J Thorac Oncol. 2008 Oct;3(10):1173-84. doi: 10.1097/JTO.0b013e318187220f. Review.

5.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

6.

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV.

J Clin Oncol. 2008 Feb 1;26(4):650-6. doi: 10.1200/JCO.2007.13.9303.

7.

Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer.

Blackstock AW, Govindan R.

J Clin Oncol. 2007 Sep 10;25(26):4146-52. Review.

PMID:
17827465
8.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.

N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.

9.

Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial.

Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF Jr, Krook JE, Rowland KM Jr, Mazurczak MA, Berg AR, Kim GP; North Central Cancer Treatment Group.

Cancer. 2005 Jul 1;104(1):176-82.

10.

Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer.

Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E.

Clin Lung Cancer. 2003 Jan;4(4):231-6.

PMID:
14624712
11.

Neovastat--a novel antiangiogenic drug for cancer therapy.

Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Béliveau R.

Anticancer Drugs. 2003 Feb;14(2):91-6. Review.

PMID:
12569294
12.

The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis.

Boivin D, Gendron S, Beaulieu E, Gingras D, Béliveau R.

Mol Cancer Ther. 2002 Aug;1(10):795-802.

13.

Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue.

Dupont E, Falardeau P, Mousa SA, Dimitriadou V, Pepin MC, Wang T, Alaoui-Jamali MA.

Clin Exp Metastasis. 2002;19(2):145-53.

PMID:
11964078
14.

The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.

Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.

Clin Cancer Res. 2002 Apr;8(4):1242-50.

15.

Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound.

Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Béliveau R.

Anticancer Res. 2001 Jan-Feb;21(1A):145-55.

PMID:
11299728
16.

Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology.

Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE.

J Clin Oncol. 2000 Jul;18(13):2505-14.

PMID:
10893280
17.

The hallmarks of cancer.

Hanahan D, Weinberg RA.

Cell. 2000 Jan 7;100(1):57-70. Review. No abstract available.

18.

Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer.

Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D.

J Clin Oncol. 1998 Nov;16(11):3649-55.

PMID:
9817287
19.

The prevalence of complementary/alternative medicine in cancer: a systematic review.

Ernst E, Cassileth BR.

Cancer. 1998 Aug 15;83(4):777-82. Review.

PMID:
9708945
20.

Supplemental Content

Support Center